Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

Elke Jäger; Julia Karbach; Sacha Gnjatic; Antje Neumann; Armin Bender; Danila Valmori; Maha Ayyoub; Erika Ritter; Gerd Ritter; Dirk Jäger; Dennis Panicali; Eric Hoffman; Linda Pan; Herbert Oettgen; Lloyd J. Old; Alexander Knuth

doi:10.1073/pnas.0606512103

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

Elke Jäger, Julia Karbach, Sacha Gnjatic, Antje Neumann, Armin Bender, Danila Valmori, Maha Ayyoub, Erika Ritter, Gerd Ritter, Dirk Jäger, Dennis Panicali, Eric Hoffman, Linda Pan, Herbert Oettgen, Lloyd J. Old, Alexander Knuth

Research output: Contribution to journal › Article › peer-review

201 Scopus citations

Abstract

NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.

Original language	English
Pages (from-to)	14453-14458
Number of pages	6
Journal	Proceedings of the National Academy of Sciences of the United States of America
Volume	103
Issue number	39
DOIs	https://doi.org/10.1073/pnas.0606512103
State	Published - 26 Sep 2006
Externally published	Yes

Keywords

Antibody response
NY-ESO-1 recombinant vaccine
T cell response
Tumor reactivity

Access to Document

10.1073/pnas.0606512103

Cite this

Jäger, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., Ayyoub, M., Ritter, E., Ritter, G., Jäger, D., Panicali, D., Hoffman, E., Pan, L., Oettgen, H., Old, L. J., & Knuth, A. (2006). Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 103(39), 14453-14458. https://doi.org/10.1073/pnas.0606512103

@article{1c7754a6c9f74bbe9d998aa40d6f4976,

title = "Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients",

abstract = "NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.",

keywords = "Antibody response, NY-ESO-1 recombinant vaccine, T cell response, Tumor reactivity",

author = "Elke J{\"a}ger and Julia Karbach and Sacha Gnjatic and Antje Neumann and Armin Bender and Danila Valmori and Maha Ayyoub and Erika Ritter and Gerd Ritter and Dirk J{\"a}ger and Dennis Panicali and Eric Hoffman and Linda Pan and Herbert Oettgen and Old, \{Lloyd J.\} and Alexander Knuth",

year = "2006",

month = sep,

day = "26",

doi = "10.1073/pnas.0606512103",

language = "English",

volume = "103",

pages = "14453--14458",

journal = "Proceedings of the National Academy of Sciences of the United States of America",

issn = "0027-8424",

publisher = "National Academy of Sciences",

number = "39",

}

Jäger, E, Karbach, J, Gnjatic, S, Neumann, A, Bender, A, Valmori, D, Ayyoub, M, Ritter, E, Ritter, G, Jäger, D, Panicali, D, Hoffman, E, Pan, L, Oettgen, H, Old, LJ & Knuth, A 2006, 'Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients', Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 39, pp. 14453-14458. https://doi.org/10.1073/pnas.0606512103

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. / Jäger, Elke; Karbach, Julia; Gnjatic, Sacha et al.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 39, 26.09.2006, p. 14453-14458.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

AU - Jäger, Elke

AU - Karbach, Julia

AU - Gnjatic, Sacha

AU - Neumann, Antje

AU - Bender, Armin

AU - Valmori, Danila

AU - Ayyoub, Maha

AU - Ritter, Erika

AU - Ritter, Gerd

AU - Jäger, Dirk

AU - Panicali, Dennis

AU - Hoffman, Eric

AU - Pan, Linda

AU - Oettgen, Herbert

AU - Old, Lloyd J.

AU - Knuth, Alexander

PY - 2006/9/26

Y1 - 2006/9/26

N2 - NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.

AB - NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.

KW - Antibody response

KW - NY-ESO-1 recombinant vaccine

KW - T cell response

KW - Tumor reactivity

UR - https://www.scopus.com/pages/publications/33749237126

U2 - 10.1073/pnas.0606512103

DO - 10.1073/pnas.0606512103

M3 - Article

C2 - 16984998

AN - SCOPUS:33749237126

SN - 0027-8424

VL - 103

SP - 14453

EP - 14458

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

IS - 39

ER -

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this